Reflections on the AGMVirtual AGMs are awful and that's reflected in the mediocre Q&A where management simply amalgamated shareholder questions into a few generic questions and then provided generic answers. I would be very curious to read the actual questions that were submitted.
The directors should be embarrassed by the voting results--assuming that they're even capable of embarrassment, that is. Usually directors win with high-80s to mid-90s. Outside of a proxy contest it's highly unusual to see results in the 70s. Matt barely broke 70%. I think that's an indictment of the board and of management. Shareholders only hope at this point is that the directors (especially the newer ones) care enough about their reputations to take some action. Seriously. I really think that.
More generally, Matt and Kirk should be fired. I know that some have been saying that for a while, but I think it's true. They can't execute. It doesn't matter how good your idea is, or how good your product is, if you can't execute, then it's worthless. And they have no credibility. I literally do not believe any timeline that they provide. Just in the past 9 months: (i) failed PanCan and delay in relaying that information to shareholders; (ii) commencing a Phase III in pancreatic by end of H1 (I believe that was in a corporate presentation at the beginning of the year); (iii) Phase IIIs are now mysteriously "registration-enabling studies". And let's not forget the many and ongoing "partnership discussions". And if we go back 12 months, I would add in Bracelet where (I believe) they blew the trial design on the CPI arm.
I've long thought that if this company had a longer operating history and better management, that we would be worth a lot more. As it is, that time is past. The board should do it's job and find a CEO who either, (i) has demonstrated experience in getting a drug through the Phase III process, or (ii) can package the company for sale. Personally, I would be quite happy with a $4-5 buy-out at this point.